ClinicalTrials.gg
RecruitingNCT05764538Updated Oct 23, 2026

DAOIB for the Treatment of Brain Fog

A Phase 2 interventional study of DAOIB in Long COVID, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · Taiwan.

Planned enrollment
7th of 11
40 · median 68
Started
2023
with 6 others
Phase 2
Only one
of the 15
Registered
6th of 15
by date
Lead sponsor
2 of 15
Chang Gung Memorial Hospital

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 7 that started in 2023, is the only one in phase 2, and was the 6th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

5 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.

03

Conditions studied

  • Long COVID
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments
  • physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits
  • have sufficient education to communicate effectively and are capable of completing the assessments of the study

Exclusion criteria

Exclusion Criteria:

  • history of significant cerebrovascular disease
  • Hachinski Ischemic Score > 4
  • major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments
  • memantine use (memantine is an NMDAR partial antagonist)
  • substance (including alcohol) abuse or dependence
  • delusion, hallucination or delirium symptoms
  • severe visual or hearing loss
  • inability to follow the protocol
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    DAOIB

    Drug: DAOIB

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

    Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)

    Time frame: week 0, 8, 16, 24

Secondary outcomes

  1. Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

    Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

    Time frame: week 8, 16, 24

  2. Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24

    The assessment appears to be a suitable instrument for evaluating activities of daily living in early-phase dementia. Its scores range from 0 (worst) to 78 (best)

    Time frame: week 0, 8, 16, 24

  3. Change from baseline in Quality of life score at week 8, 16 and 24

    Quality of life will be assessed by Medical Outcomes Study Short-Form-36 (SF-36). The SF-36 consists of eight sections: (1) vitality, (2) physical functioning, (3) bodily pain, (4) general health perceptions, (5) physical role functioning, (6) emotional role functioning, (7) social role functioning, and (8) mental health.

    Time frame: week 0, 8, 16, 24

  4. Change from baseline of 17-item Hamilton Rating Scale for Depression

    Assessment of depressive symptoms. The 17-item Hamilton Rating Scale for Depression will be measured every 8 weeks

    Time frame: week 0, 8, 16, 24

  5. Change from baseline of Hamilton Anxiety Rating Scale

    Assessment of anxiety symptoms. The Hamilton Anxiety Rating Scale will be measured every 8 weeks

    Time frame: week 0, 8, 16, 24

  6. Change from baseline of Perceived Stress Scale

    Assessment of stress and anxiety symptoms. The Perceived Stress Scale will be measured every 8 weeks

    Time frame: week 0, 8, 16, 24

  7. Change from baseline in the score of a battery of additional cognitive tests

    The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (Wechsler Memory Scale, Spatial Span), verbal/nonverbal learning and memory tests (Wechsler Memory Scale, Word Listing)

    Time frame: week 0, 8, 16, 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 52 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 10, 2023
StartActual
Feb 27, 2023
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2027was Jun 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Oct 23, 2026
Study completion
Jun 2026→Jun 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Jun 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05764538
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Feb 27, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Benzoate

Start the discussion